Wu et al. 2011

Retrospective Cohort Study

CEBM Level 4

Heyland Score (/11): 5

Total = 61

J-tube: 29 (47.5%)

No J-tube: 32 (52.5%)

Nil Reported

Change in Body Weight^{^^}:

−7.1 kg ± 3.3 JT vs. 9.9 kg ± 3.1 No JT*

Change in BMI^{^^}:

−2.4 ± 1.0 JT vs. −3.2 ± 0.9 No JT*

At Risk of Undernutrition Post-Operatively

(NRS ≥ 3)*: 24.1% JT vs. 65.6% No JT*

Postoperative KPS Improvement:

58.6% JT vs. 21.9% No JT*

Chemotherapy Endurance:

4.0 ± 2.0 Doses JT vs 3.0 ± 2.0 Doses No JT

Chemotherapy Adverse Drug Reactions:

Lower Tendency in JT Group

Postoperative Total Lymphocyte Count (×10⁹/L):

1.7 ± 0.6 JT vs. 1.5 ± 0.6 No JT

Postoperative Hb (g/L):

118.9 ± 17.5 JT vs. 126.8 ± 17.8 No JT

Postoperative Albumin (g/L):

42.8 ± 5.3 JT vs. 40.4 ± 5.6 No JT